Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$34.24

-0.37 (-1.07%)

, JNJ

Johnson & Johnson

$133.19

0.3 (0.23%)

06:20
10/06/17
10/06
06:20
10/06/17
06:20

Bayer's Navigate Esus study halted early, had comparable efficacy in arms

Bayer (BAYRY) and its development partner Janssen Research & Development (JNJ) yesterday announced that the Phase III NAVIGATE ESUS study evaluating the efficacy and safety of rivaroxaban -- Xarelto -- for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source has been stopped early. Based on the recommendation by the Independent Data Monitoring Committee following a planned interim analysis, the trial was halted early as it showed comparable efficacy between the rivaroxaban and aspirin arms and very little chance of showing overall benefit if the study were completed. While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm. The decision to halt the trial was taken jointly by the Academic Leadership of the trial and the sponsor Bayer. The Phase III NAVIGATE ESUS study has enrolled 7,214 patients from 459 sites across 31 countries worldwide. In the study, patients were randomized to receive either rivaroxaban 15 mg once daily or aspirin 100 mg once daily alone. The primary efficacy endpoint was a composite of stroke and systemic embolism. The primary safety endpoint was major bleeding according to the criteria of the International Society on Thrombosis and Haemostasis. A complete data analysis is expected to be presented at an upcoming medical meeting in 2018.

BAYRY

Bayer

$34.24

-0.37 (-1.07%)

JNJ

Johnson & Johnson

$133.19

0.3 (0.23%)

  • 08

    Oct

  • 17

    Oct

  • 23

    Oct

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

BAYRY Bayer
$34.24

-0.37 (-1.07%)

08/18/17
UBSW
08/18/17
DOWNGRADE
Target $128
UBSW
Neutral
Monsanto downgraded to Neutral from Buy at UBS
UBS analyst John Roberts downgraded Monsanto (MON) to Neutral saying the shares are now less than 10% away from the accepted Bayer (BAYRY) offer of $128. The analyst calculates that the market is currently pricing in a 70% chance of the deal going through. His view that the deal could be approved remains unchanged. Approvals of peer deals suggest antitrust approval likely for Monsanto, Roberts tells investors in a research note. The analyst keeps a $128 price target for Monsanto shares.
09/05/17
BERN
09/05/17
NO CHANGE
BERN
Bernstein still sees 'very high' probability of Bayer, Monsanto deal approval
Bernstein analyst Jeremy Redenius notes that the European Commission has opened an in-depth review of the Bayer (BAYRY)/Monsanto (MON) deal due to concerns of reduced competition in pesticides, seeds, and traits. The analyst believes this is not surprising, as the in-depth review is the norm for deals of this size. Comparing the EC's initial concerns with those of the Dow/DuPont (DWDP) deal, he still sees a "very high" probability of deal approval.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.
10/03/17
RHCO
10/03/17
NO CHANGE
RHCO
TG Therapeutics has positive read through from Bayer approval, says SunTrust
SunTrust analyst Yatin Suneja believes that the FDA's decision to grant accelerated approval to Bayer's (BAYRY) Aliqopa, a PI3K-delta inhibitor, as a treatment for Relapsed/Refractory Follicular Lymphoma, bodes well for TG Therapeutics' (TGTX) own PI3K-delta inhibitor, TGR-120. The analyst says that the lack of a black box warning on Bayer's Aliqopa shows that not all PI3K-delta inhibitors have the safety issues that have been attributed to them in the past. Suneja says that "Aliqopa's approval reflects positively on TGR-1202, which offers best-in-class safety , and provides clarity on TGR-1202's regulatory pathway in" lymphoma The analyst says that investors are "overlooking" its potential in " lymphoma, and keeps a Buy rating on the shares.
JNJ Johnson & Johnson
$133.19

0.3 (0.23%)

09/25/17
09/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) initiated with a Neutral at Citi. 2. CoreSite Realty (COR) initiated with a Neutral at JPMorgan. 3. Hi-Crush Partners (HCLP) initiated with an Overweight at Piper Jaffray. 4. Zillow (Z, ZG) initiated with a Neutral at Macquarie. 5. Big Lots (BIG) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/17
SBSH
10/03/17
NO CHANGE
SBSH
Citi's general surgery survey 'very positive' for Intuitive Surgical
Citi analyst Amit Hazan says his firm's general surgery survey is "very positive" for Intuitive Surgical (ISRG), and "much less so" for Medtronic (MDT) and Johnson & Johnson (JNJ). Robotic procedures are expected to be up about 30% this year and next, with ventral hernia leading, Hazan tells investors in a research note partially titled "It's a Good Time to be a Robot." He believes robotic is really starting to hurt laparoscopy and that Medtronic and J&J will likely be forced to talk about the headwind publicly.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.

TODAY'S FREE FLY STORIES

00:00
02/22/18
02/22
00:00
02/22/18
00:00
General news
Breaking General news story  »

Federal Reserve Vice…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:29
02/21/18
02/21
18:29
02/21/18
18:29
Earnings
Valmont sees 2018 adjusted $8.00, consensus $8.15 »

Sees 2018 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:27
02/21/18
02/21
18:27
02/21/18
18:27
Earnings
Valmont reports Q4 adjusted EPS $1.67, consensus $1.69 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

CTRV

ContraVir Pharmaceuticals

$0.25

-0.013 (-5.00%)

18:11
02/21/18
02/21
18:11
02/21/18
18:11
Hot Stocks
ContraVir Pharmaceuticals' hepatitis B treatment receives FDA Orphan designation »

ContraVir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:06
02/21/18
02/21
18:06
02/21/18
18:06
Earnings
AAC Holdings sees FY18 adjusted EPS 70c-75c, consensus 53c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:05
02/21/18
02/21
18:05
02/21/18
18:05
Earnings
AAC Holdings reports Q4 adjusted EPS 10c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DNKN

Dunkin' Brands

$60.70

-1.45 (-2.33%)

18:04
02/21/18
02/21
18:04
02/21/18
18:04
Hot Stocks
Baskin-Robbins expands in Toronto with plans for four new locations »

Baskin-Robbins, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$102.43

0.05 (0.05%)

18:01
02/21/18
02/21
18:01
02/21/18
18:01
Hot Stocks
Celanese to increase price of acetyl intermediate products »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

TUSK

Mammoth Energy

$20.04

-0.11 (-0.55%)

17:56
02/21/18
02/21
17:56
02/21/18
17:56
Earnings
Mammoth Energy reports Q4 EPS $1.48, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NSPR

InspireMD

$4.20

-0.26 (-5.83%)

17:53
02/21/18
02/21
17:53
02/21/18
17:53
Syndicate
Breaking Syndicate news story on InspireMD »

InspireMD files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$51.76

-0.25 (-0.48%)

17:52
02/21/18
02/21
17:52
02/21/18
17:52
Syndicate
Breaking Syndicate news story on E-Trade »

E-Trade files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$39.91

1.01 (2.60%)

17:47
02/21/18
02/21
17:47
02/21/18
17:47
Syndicate
Breaking Syndicate news story on Spirit Airlines »

Spirit Airlines files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAND

Bandwidth

$24.09

0.18 (0.75%)

, CAR

Avis Budget

$38.96

-0.98 (-2.45%)

17:42
02/21/18
02/21
17:42
02/21/18
17:42
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

BAND

Bandwidth

$24.09

0.18 (0.75%)

CAR

Avis Budget

$38.96

-0.98 (-2.45%)

MB

Mindbody

$33.35

-0.1 (-0.30%)

SAIL

SailPoint Technologies

$17.92

0.47 (2.69%)

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

GPOR

Gulfport Energy

$8.41

-0.32 (-3.67%)

SNPS

Synopsys

$88.46

-1.3 (-1.45%)

PE

Parsley Energy

$23.10

-0.19 (-0.82%)

P

Pandora

$4.87

-0.46 (-8.63%)

MLNX

Mellanox

ROKU

Roku

$51.10

-0.08 (-0.16%)

AAOI

Applied Optoelectronics

$34.55

1.22 (3.66%)

SRCL

Stericycle

$74.91

-0.31 (-0.41%)

CSLT

Castlight Health

$3.85

0.3 (8.45%)

UCTT

Ultra Clean

$19.96

-0.4 (-1.96%)

TRN

Trinity Industries

$35.23

0.47 (1.35%)

RGR

Sturm, Ruger

$47.30

-1.05 (-2.17%)

CONE

CyrusOne

$48.81

-1.56 (-3.10%)

ADXS

Advaxis

$2.51

-0.08 (-3.09%)

GWPH

GW Pharmaceuticals

$132.33

1.5 (1.15%)

OMF

OneMain Holdings

$31.67

-0.22 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 11

    Mar

  • 13

    Mar

  • 14

    Mar

  • 21

    Mar

  • 26

    Mar

  • 28

    Mar

  • 29

    Mar

  • 03

    Apr

  • 15

    May

  • 23

    May

  • 27

    Jun

  • 22

    Feb

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:40
02/21/18
02/21
17:40
02/21/18
17:40
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:39
02/21/18
02/21
17:39
02/21/18
17:39
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.